At the news
? NEUTRALIMPACT 6/10 DEFA14A filed Nov 9, 2026 at 17:19 ET
Lisata Therapeutics adjourned its 2026 annual meeting solely on Proposal No. 3 (conversion of Series C Preferred Stock, which would represent >20% of outstanding shares and result in a change of control) to November 30, 2026, to allow more time for proxy solicitation and Nasdaq listing application approval. The board continues to unanimously recommend a FOR vote. All other proposals were voted on and results will be reported in a separate 8-K.
- Annual meeting convened November 9, 2026; votes taken on Proposals 1, 2, 4, 5, 6, 7, and 8.
- Meeting adjourned solely on Proposal No. 3 (Conversion Proposal) to allow more time for proxy solicitation and Nasdaq listing application approval.
- Reconvened meeting set for November 30, 2026 at 11:00 a.m. ET, virtual only.
- Conversion Proposal seeks approval of common stock issuance upon conversion of Series C Preferred Stock, representing >20% of outstanding shares and resulting in a change of control under Nasdaq rules.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access